ESA REMS Allows Oncology Providers One Year To Enroll Before Possible Distribution Limits
This article was originally published in The Pink Sheet Daily
Executive Summary
The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment.
You may also be interested in...
Affymax Plans For Peginesatide Launch
The biotech is making plans with its Japanese partner for the launch of its new ESA that is awaiting approval.
Affymax Plans For Peginesatide Launch
The biotech is making plans with its Japanese partner for the launch of its new ESA that is awaiting approval.
Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More
The Indian drug maker has officially kept its biosimilar pipeline secret but has indicated that it includes a pegylated molecule in late-stage clinical trials, two other products scheduled to enter clinical trials, and several others in early stage development.